Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger

Fernandopulle SM, Cher-Siangang P, Tan PH (2006) Breast carcinoma in women 35 years and younger: a pathological study. Pathology 38:219–222 Figueiredo JC, Ennis M, Knight JA et al (2007) Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 105:69–80 Armes JE, Egan AJ, Southey MC et al (1998) The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83:2335–2345 Bennett IC, Freitas R Jr, Fentiman IS (1991) Diagnosis of breast cancer in young women. Aust N Z J Surg 61:284–289 Tai P, Cserni G, Van de Steene J et al (2005) Modeling the effect of age in T1-T2 breast cancer using the SEER database. BMC Cancer 5:130. doi:10.1186/1471-2407-5-130 Trecate G, Vergnaghi D, Manoukian S et al (2006) MRI in the early detection of breast cancer in women with high genetic risk. Tumori 92:517–523 Golshan M, Miron A, Nixon AJ (2006) The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 192:58–62 Lubiński J, Górski B, Huzarski T et al (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71–76 Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71:165–170 Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835 Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034 Laakso M, Loman N, Borg A et al (2005) Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18:1321–1328 Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180 Lidereau R, Eisinger F, Champeme MH et al (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60:1206–1210 Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485 Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22–34 Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874 Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423 Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374 Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728 Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32 Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410 Ellis IO, Pinder SE, Bobrow L et al (2005) Pathology reporting of breast disease. NHS Publication No 58. Sheffield: NHS Cancer Screening Programmes and the Royal College of Pathologists. Accessed at 12 July 2007. http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58-low-resolution.pdf DakoCytomation. HercepTestTM, 8th ed. Accessed at 12 July 2007. http://dist.dako.com/prod_downloadpackageinsert.pdf?objectid=105073005 Takei H, Iino Y, Horiguchi J et al (1997) Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol Rep 4:33–38 Ridolfi RL, Rosen PP, Port A et al (1977) Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40:1365–1385 Tot T (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37:175–181 Jacquemier J, Padovani L, Rabayrol L et al (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207:260–268 Reis-Filho JS, Milanezi F, Steele D et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49:10–21 Tsuda H, Takarabe T, Hasegawa F et al (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197–202 Bratthauer GL, Miettinen M, Tavassoli FA (2003) Cytokeratin immunoreactivity in lobular intraepithelial neoplasia. J Histochem Cytochem 51:1527–1531 van ’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536 Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729–735